Volume 23, Number 4—April 2017
Significant Decrease in Pertactin-Deficient Bordetella pertussis Isolates, Japan
Highlight and copy the desired format.
|EID||Hiramatsu Y, Miyaji Y, Otsuka N, Arakawa Y, Shibayama K, Kamachi K, et al. Significant Decrease in Pertactin-Deficient Bordetella pertussis Isolates, Japan. Emerg Infect Dis. 2017;23(4):699-701. https://dx.doi.org/10.3201/eid2304.161575|
|AMA||Hiramatsu Y, Miyaji Y, Otsuka N, et al. Significant Decrease in Pertactin-Deficient Bordetella pertussis Isolates, Japan. Emerging Infectious Diseases. 2017;23(4):699-701. doi:10.3201/eid2304.161575.|
|APA||Hiramatsu, Y., Miyaji, Y., Otsuka, N., Arakawa, Y., Shibayama, K., & Kamachi, K. (2017). Significant Decrease in Pertactin-Deficient Bordetella pertussis Isolates, Japan. Emerging Infectious Diseases, 23(4), 699-701. https://dx.doi.org/10.3201/eid2304.161575.|
Prevalence of pertactin-lacking Bordetella pertussis isolates has been observed worldwide. In Japan, however, we found that the frequency of pertactin-deficient isolates in 2014–2016 (8%) was significantly lower than the frequency in 2005–2007 (41%), 2008–2010 (35%), and 2011–2013 (25%). This reduction was closely associated with changes in genotypes.
Bordetella pertussis, a highly communicable, gram-negative coccobacillus, is the etiologic agent of pertussis (whooping cough), an acute respiratory infection that leads to severe illness in children. Vaccination is the most effective method for preventing and controlling pertussis. In Japan, acellular pertussis vaccines (ACVs) were introduced in 1981. Pertussis toxin and filamentous hemagglutinin derived from B. pertussis are the major antigens in ACVs in Japan, and certain ACVs also contain pertactin and fimbriae (1). Pertactin is believed to play a role in adherence to human epithelial cells (2); however, B. pertussis isolates that lack pertactin production have been identified in several countries where ACVs have been introduced (3–7). In Japan, pertactin-deficient isolates have increased significantly since the early 2000s, resulting in a high prevalence of these isolates (5,8). Recent studies have demonstrated that pertactin-deficient strains could colonize the respiratory tract more effectively than pertactin-producing strains in ACV-vaccinated mice (9,10). Supporting these results, an epidemiologic study suggested that ACV-vaccinated persons are more susceptible to pertactin-deficient strains than to pertactin-producing strains (11). These reports imply that pertactin-deficient strains have increased fitness in humans who have been vaccinated with ACVs and that their expansion may reduce the effectiveness of ACVs. We assessed trends in the frequency of pertactin-deficient isolates in Japan and further investigated their genotypes using multilocus variable-number tandem-repeat analysis (MLVA).
We studied 232 B. pertussis clinical isolates collected from January 2005 through June 2016 in Japan. All isolates were derived from epidemiologically unrelated cases of pertussis. Pertactin production and MLVA types (MTs) of 111 isolates collected during 2005–2012 were previously determined by immunoblotting and MLVA typing, respectively (5,8). For our study, we extended these analyses to additional isolates collected during 2008–2016 (n = 121).
We determined the temporal trend in the frequency of pertactin-deficient isolates by 3-year periods (Figure, panel A). Percentages were 41% in 2005–2007 (n = 39 isolates), 35% in 2008–2010 (n = 43), 25% in 2011–2013 (n = 97), and 8% in 2014–2016 (n = 53). A significant decrease in the frequency of pertactin-deficient isolates was observed from 2005–2007 to 2014–2016 (p<0.05 by Fisher exact test).
Among the 232 B. pertussis isolates, 25 MTs were identified; MT27 and MT186 isolates were predominant, and other MT isolates were found at low frequencies (Technical Appendix [PDF - 376 KB - 6 pages] Table 1). The frequency of MT27 isolates increased significantly over time (Figure 1, panel B): 28% in 2005–2007, 44% in 2008–2010, 70% in 2011–2013, and 77% in 2014–2016. In contrast, the frequency of MT186 isolates decreased: 31% in 2005–2007, 44% in 2008–2010, 21% in 2011–2013, and 6% in 2014–2016. We also observed a substitution of the major genotype in the B. pertussis population from MT186 to MT27.
Of 59 pertactin-deficient B. pertussis isolates collected during 2005–2016, 45 (76.3%) were MT186 isolates, whereas 2 (3.4%) represented MT27 and 12 (20.3%) other MT isolates (MT194, MT224–226, MT314–316) (Table). Notably, 45 (83.3%) of 54 MT186 isolates were pertactin-deficient, whereas only 2 (1.4%) of 139 MT27 isolates were pertactin-deficient. This finding indicates that pertactin-deficient isolates predominate among the MT186 strain but are rare among the MT27 strain.
We previously showed that pertactin-deficient isolates in Japan were generated by 2 different mutations: an 84-bp deletion of the prn gene signal sequence (ΔSS) and an IS481 insertion at nucleotide position 1598 in prn (1598–1599::IS481) (5). Thus, to confirm the molecular basis for the loss of pertactin production, pertactin-deficient isolates (n = 26) that were newly identified in this study underwent PCR screening with 2 primer sets (Technical Appendix [PDF - 376 KB - 6 pages] Table 2). We summarized the molecular mechanisms of loss of pertactin production in 59 pertactin-deficient isolates (Table); the ΔSS mutation was detected in 43 (72.9%) MT186 isolates and in 11 (18.6%) other MT isolates. In contrast, the 1598–1599::IS481 mutation was detected in 2 (3.4%) MT186 isolates and 1 other MT isolate (1.7%, MT226). Two MT27 isolates (BP394 and BP533) do not have either of these mutations. Instead, BP533 isolates (1.7%) have an IS481 insertion at nucleotide position 245 (245–246::IS481; GenBank accession no. KC445198), and BP394 (1.7%) isolates exhibit transcriptional down-regulation of prn gene expression (Technical Appendix [PDF - 376 KB - 6 pages] Figure 1).
The expansion of pertactin-deficient B. pertussis isolates has been reported worldwide (3–8). However, we observed a significant decrease in pertactin-deficient isolates within the B. pertussis population in Japan, caused by a genotypic replacement from the pertactin-deficient MT186 strain to the pertactin-producing MT27 strain.
The most likely explanation for the prevalence of pertactin-deficient strains is vaccine-driven strain evolution, because pertactin is a component of ACVs. No pertactin-deficient isolates have been detected in Denmark, where an ACV that does not contain pertactin is used, and pertactin-deficient strains exhibit a selective advantage against ACV-induced immunity (7,9–11). In Japan, 5 brands of the diphtheria–tetanus–acellular pertussis vaccine (DTaP) had been used to control pertussis for many years. These DTaPs had different formulations of components; only 3 contained the pertactin antigen (1). When the DTaP vaccine was replaced, however, 2 brands of combined DTaP–inactivated poliovirus (DTaP-IPV) vaccine that did not contain pertactin were introduced in November 2012. Therefore, most Japanese children <4 years of age do not have immunity to pertactin; consequently, the selective pressure for pertactin-deficient strains in the host environment has recently been reduced. This effect may be responsible for the recent decline in pertactin-deficient isolates and further supports the hypothesis that pertactin-deficient strains are selected on the basis of host immunity to pertactin. Notably, a new brand of DTaP-IPV vaccine containing pertactin was also introduced in December 2015 in Japan. If the hypothesis of vaccine-driven evolution is correct, pertactin-deficient isolates should increase again in Japan in the near future. Thus, continued surveillance of pertactin-deficient isolates is of particular value.
We demonstrated that genotypic replacement from MT186 to MT27 has taken place among recent B. pertussis isolates in Japan: MT27 is a triple-locus variant of MT186. MT186 strains carry the pertussis-toxin promoter allele ptxP1, whereas MT27 strains carry the allele ptxP3 (8). B. pertussis strains carrying ptxP3 (i.e., MT27) produce more of several virulence factors than do ptxP1 (i.e., MT186) strains (12,13). The population of MT27 strains carrying ptxP3 has increased worldwide (14,15), although a low frequency of ptxP1 isolates was observed in Japan (8), suggesting that MT27 strains are associated with the recent pertussis resurgence. It is possible, therefore, that the genotypic replacement in the B. pertussis population may have resulted from the expansion of the more virulent ptxP3 (i.e., MT27) strains. In addition, given that pertactin-deficient MT27 isolates are rare, this genotypic replacement may have contributed to the recent decrease in pertactin-deficient isolates in Japan.
In Japan, most pertactin-deficient isolates carry a deletion of the prn signal sequence (ΔSS), which has been found primarily in MT186 isolates carrying the prn1 allele (Technical Appendix [PDF - 376 KB - 6 pages] Table 1). In other countries, a common prn mutation includes an insertion of IS481 into the prn2 allele (4,6,7). In this study, we identified 2 pertactin-deficient MT27 isolates carrying the prn2 allele, due to the IS481 insertion (245–246::IS481) and the transcriptional down-regulation of the prn gene. These pertactin-deficient isolates were previously identified in Europe and the United States (6,7). One possible explanation for the appearance of pertactin-deficient MT27 isolates is that they were imported from other countries.
Dr. Hiramatsu is a research scientist at the National Institute of Infectious Diseases in Tokyo, Japan. His research interests focus on the epidemiology, pathogenesis, and development of pertussis vaccines.
This study was supported by the following funding sources: Research on Emerging and Re-emerging Infectious Diseases from the Ministry of Health, Labor, and Welfare of Japan; Research Program on Emerging and Re-emerging Infectious Diseases from the Japan Agency for Medical Research and Development.
- Okada K, Komiya T, Yamamoto A, Takahashi M, Kamachi K, Nakano T, et al. Safe and effective booster immunization using DTaP in teenagers. Vaccine. 2010;28:7626–33.
- Leininger E, Roberts M, Kenimer JG, Charles IG, Fairweather N, Novotny P, et al. Pertactin, an Arg-Gly-Asp-containing Bordetella pertussis surface protein that promotes adherence of mammalian cells. Proc Natl Acad Sci U S A. 1991;88:345–9.
- Bouchez V, Brun D, Cantinelli T, Dore G, Njamkepo E, Guiso N. First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin. Vaccine. 2009;27:6034–41.
- Lam C, Octavia S, Ricafort L, Sintchenko V, Gilbert GL, Wood N, et al. Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia. Emerg Infect Dis. 2014;20:626–33.
- Otsuka N, Han HJ, Toyoizumi-Ajisaka H, Nakamura Y, Arakawa Y, Shibayama K, et al. Prevalence and genetic characterization of pertactin-deficient Bordetella pertussis in Japan. PLoS One. 2012;7:e31985.
- Pawloski LC, Queenan AM, Cassiday PK, Lynch AS, Harrison MJ, Shang W, et al. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States. Clin Vaccine Immunol. 2014;21:119–25.
- Zeddeman A, van Gent M, Heuvelman CJ, van der Heide HG, Bart MJ, Advani A, et al. Investigations into the emergence of pertactin-deficient Bordetella pertussis isolates in six European countries, 1996 to 2012. Euro Surveill. 2014;19:20881.
- Miyaji Y, Otsuka N, Toyoizumi-Ajisaka H, Shibayama K, Kamachi K. Genetic analysis of Bordetella pertussis isolates from the 2008-2010 pertussis epidemic in Japan. PLoS One. 2013;8:e77165.
- Hegerle N, Dore G, Guiso N. Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine. Vaccine. 2014;32:6597–600.
- Safarchi A, Octavia S, Luu LD, Tay CY, Sintchenko V, Wood N, et al. Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model. Vaccine. 2015;33:6277–81.
- Martin SW, Pawloski L, Williams M, Weening K, DeBolt C, Qin X, et al. Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage. Clin Infect Dis. 2015;60:223–7.
- King AJ, van der Lee S, Mohangoo A, van Gent M, van der Ark A, van de Waterbeemd B. Genome-wide gene expression analysis of Bordetella pertussis isolates associated with a resurgence in pertussis: elucidation of factors involved in the increased fitness of epidemic strains. PLoS One. 2013;8:e66150.
- Mooi FR, van Loo IH, van Gent M, He Q, Bart MJ, Heuvelman KJ, et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis. 2009;15:1206–13.
- Schmidtke AJ, Boney KO, Martin SW, Skoff TH, Tondella ML, Tatti KM. Population diversity among Bordetella pertussis isolates, United States, 1935-2009. Emerg Infect Dis. 2012;18:1248–55.
- van Gent M, Heuvelman CJ, van der Heide HG, Hallander HO, Advani A, Guiso N, et al. Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998-2012. Eur J Clin Microbiol Infect Dis. 2015;34:821–30.
- Figure. Temporal trends in the frequency of pertactin-deficient isolates and changes in multi-locus variable-number tandem repeat analysis types (MTs) in the Bordetella pertussis population in Japan. Pertactin production (A) and MTs...
- Table. Molecular mechanisms of loss of pertactin production in 59 pertactin-deficient Bordetella pertussis isolates, Japan, 2005–2016
- . Technical Appendix. Table showing characteristics of isolates, Japan, 2005–2016, table showing primers used in the study of isolates, Japan, 2008–2016, and figure showing lack of transcript expression... 376 KB
Please use the form below to submit correspondence to the authors or contact them at the following address:
Yukihiro Hiramatsu, Department of Bacteriology II, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama, Tokyo 208-0011, Japan
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: March 16, 2017
- Page last updated: March 16, 2017
- Page last reviewed: March 16, 2017
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)